Managing severe cancer pain: The role of transdermal buprenorphine: A systematic review

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 707-718

  Deandrea, S ^a,b   Corli, O ^a   Moschetti, I ^a   Apolone, Giovanni ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Cancer pain; Systematic review; Transdermal buprenorphine

Indexed keywords

BUPRENORPHINE; FENTANYL; HYDROMORPHONE; MORPHINE;

CANCER PAIN; CANCER PATIENT; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFUSION; CONSTIPATION; DISEASE SEVERITY; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; GASTROINTESTINAL SYMPTOM; HUMAN; META ANALYSIS; NAUSEA; PAIN ASSESSMENT; PRURITUS; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SIDE EFFECT; SKIN TOXICITY; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL ANALOG SCALE; VOMITING;

EID: 77949471808     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Hearn J, Higginson IJ. Cancer pain epidemiology: a systematic review. In: Bruera ED, Portenoy RK, editors. Cancer Pain, Assessment and Management. Cambridge: Cambridge University Press; 2003.
2. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18:1437-1449.
3. Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol. 2008;19:1985-1991.
4. World Health Organization. Cancer Pain Relief. 2nd ed. Geneva: W.H.O; 1996.
5. Jacox A, Carr DB, Payne R. New clinical-practice guidelines for the management of pain in patients with cancer. N Engl J Med. 1994;330:651-655.
6. SIGN: Scottish intercollegiate guideline network. Control of pain in patients with cancer. A national clinical guideline. SIGN publication number 44, June 2000.
7. Hanks G, De Conno F, Cherny N, et al; for Expert Working Group of the Research Network of the European Association for Palliative Care. Morphine and alternative opioids in cancer pain the EAPC recommendations. Br J Cancer. 2001;84:587-593.
8. Skaer TL. Transdermal opioids for cancer pain. Health Qual Life Outcomes. 2006;31:4-24.
9. Kress HG. Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain. 2009;13:219-230.
10. McQuay HJ, Moore RA. Buprenorphine kinetics in humans. In: Cowan A, Lewis JW, editors. Buprenorphine: Combating Drug Abuse with a Unique Opioid. New York: Wiley-Liss; 1995:137-147.
11. Weinberg DS, Inturrisi CE, Reidembreg B, et al. Sublingual absorption of selected opioid analgesics. Clin Pharmacol Ther. 1988;44:335-342.
12. Garrett ER, Chandran VR. Pharmacokinetics of morphine and its surrogates: bioanalysis, solvolysis kinetics, solubility, pKa values and protein binding of buprenorphine. J Pharmaceut Sci. 1985;74:515-524.
13. Huang P, Kehner GB, Cowan A, et al. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther. 2001;297:688-695.
14. Cowan A. update on the general pharmacology of buprenorphine. In: Cowan A, Lewis JW, editors. Buprenorphine: Combating Drug Abuse with a Unique Opioid. New York: Wiley-Liss; 1995:31-47.
15. 35S)thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol. 1995;47:848-854.
16. Selley DA, Liu Q, Childers SR. Signal transduction correlates of mu-opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus. J Pharmacol Exp Ther. 1998;285:496-505.
17. Toll L, Berzetei-Gurske IP, Polgar WE, et al. Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications. NIDA Res Monogr. 1998;178:440-466.
18. Lee K, Akil H, Woods JH, et al. Novel binding properties of oripavines at a cloned mu-opioid receptor. Eur J Pharmacol. 1999;378:323-330.
19. Romero DV, Partilla JS, Zheng QX, et al. Opioid peptide receptor studies. Buprenorphine is a potent and selective mu/kappa antagonist in the [35S]-GTP-gamma-S functional binding assay. Synapse. 1999;34:83-94.
20. Zhu J, Luo LY, Chen C, et al. Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands. J Pharmacol Exp Ther. 1997;282:676-684.
21. Dahan A, Yassen A, Romberg R, et al. Buprenorphine induces ceiling in respiratory depression but not in analgesia. Br J Anaesth. 2006;96:627-632.
22. Rothman RB. Buprenorphine: a review of the binding literature. In: Cowan A, Lewis JW, editors. Buprenorphine: Combating Drug Abuse with a Unique Opioid. New York: Wiley-Liss; 1995. p. 19-29.
23. Villiger JW, Taylor KM. Buprenorphine: characteristics of binding sites in the rat central nervous system. Life Sci. 1981;29:2699-2708.
24. Sidhu BS, Khichy S, Singh KH. Comparative evaluation of intramuscular buprenorphine, pentazocine and nefopam in postoperative pain relief. J Ind Med Assoc. 1993;91:288-289.
25. Evans HC, Easthoper SE. Transdermal buprenorphine. Drugs. 2003;63:1999-2010.
26. Johnson RE, Fuadala PJ, Payne R. Buprenorphine: considerations for pain management. J Pain Symptom Manage. 2005;29:297-396.
27. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration, 2008.
28. Böhme K, Likar R. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS) in the treatment of patients with chronic pain. A randomized, double-blind, placebo-controlled study. Pain Clinic. 2003;15:193-202.
29. Radbruch L, Vielvoye-Kerkmeer A. Buprenorphine TDS: the clinical development- rationale and results. J Clin Pract Suppl. 2003;133:15-28.
30. Radbruch L. Buprenorphine TDS: use in daily practice, benefits for patients. Int J Clin Pract Suppl. 2003;133:19-22.
31. Sittl R, Griessinger N, Likar R, Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther. 2003;25:150-168.
32. Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a Phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2004;26:1808-1820.
33. Griessinger N, Sittl R, Likar R. Transdermal buprenorphine in clinical practice- post-marketing surveillance study of 13,179 patients. Curr Med Res Opin. 2005;21:1147-1156.
34. Muriel C, Failde I, Micò JA, Neira M, Sanchez-Magro I. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study. Clin Ther. 2005;27:451-462.
35. Apolone G, Mangano S, Compagnoni A, et al; for Cancer Pain Outcome Research Group. A multidisciplinary project to improve the quality of cancer pain management in Italy. J Ambulatory Care Manage. 2006;29:332-341.
36. Likar R, Kayser H, Sittl R. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials. Clin Ther. 2006;28:943-952.
37. Mercadante S, Ferrera P, Villari P. Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients. Support Care Cancer. 2007;15:441-444.
38. Camba M, Rodriguez-Lopez MJ, Muriel C. Buprenorphine TDS in the treatment of chronic nociceptive, neuropathic and cancer-related pain. J Appl Ther Res. 2007;6:3-13.
39. Freye E, Anderson-Hillemacher A, Ritzdorf I, Levy JV. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec®) in chronic pain patients. Pain Practice. 2007;7:123-129.
40. Likar R, Lorenz V, Korak-Leite M, Kager I, Sittl R. Transdermal buprenorphine patches applied in a 4-day regimen versus 3-day regimen: a single-site, phase III, randomized, open-label, crossover comparison. Clin Ther. 2007;29:1591-1606.
41. Mercadante S, Porzio G, Fulfaro F, et al. Switching from transdermal drugs: an observational "N of 1" study of fentanyl and burenorphine. J Pain Symptom Manage. 2007;532-538.
42. Pace MC, Passavanti MB, Grella E, et al. Buprenorphine in longterm control of chronic pain in cancer pain. Front Biosci. 2007;12:1291-1299.
43. Likar R, Vadlau EM, Breschan C, Kager I, Korak-Leiter M, Ziervogel G. Comparable analgesic efficacy of transdermal buprenorphine in patients over and under 65 years of age. Clin J Pain. 2008;24:536-543.
44. Poulain P, Denier W, Douma J, et al. Efficacy and safety of transdermal buprenorphine: a randomized, placebo-controlled trial in 289 patients with severe cancer pain. J Pain Symptom Manage. 2008;36:117-125.
45. Wirz S, Wittmann M, Schenk M, et al. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral-sustained release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain. 2008; DOI:10.1016/j.ejpain.2008.09.005.
46. Apolone G, Corli O, Negri E, Mangano S, Montanari M, Greco MT; on behalf of the writing protocol committee and the Cancer Pain Outcome Research Study Group (CPOR SG) Investigators. Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients. Results from the Cancer Pain Outcome Research (CPOR) Study Group. Clin J Pain. In press. 2009.
47. Hjermstad MJ, Gibbins J, Haugen DF, Caraceni A, Loge JH, Kaasa S; for EPCRC, European Palliative Care Research Collaborative. Pain assessment tools in palliative care: an urgent need for consensus. Palliat Med. 2008;22:895-903.
48. Kaasa S, Loge JH, Fayers P, et al. Symptom assessment in palliative care: a need for international collaboration. J Clin Oncol. 2008;26:3867-3873.
49. Zeppetella G, Wiffen PJ. Buprenorphine for cancer pain. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No: CD006766. DOI: 10.1002/14651858.CD006766.
50. Apolone G, Corli O, Caraceni A, et al; for Cancer Pain Outcome Research Study Group (CPOR SG) Investigators. Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group (CPOR SG). Br J Cancer. 2009;100:1566-1574.